Suresh E. Kurhade
YOU?
Author Swipe
View article: Development of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes
Development of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes Open
View article: Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform
Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform Open
Despite the success of first, second and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in treatment of non-small cell lung cancer (NSCLC) with classical EGFR mutations (L858R or Exon 19 deletion…
View article: Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform
Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform Open
Despite the success of first, second and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in treatment of non-small cell lung cancer (NSCLC) with classical EGFR mutations (L858R or Exon 19 deletion…
View article: Disrupting N-Glycosylation Using Type I Mannosidase Inhibitors Alters B-Cell Receptor Signaling
Disrupting N-Glycosylation Using Type I Mannosidase Inhibitors Alters B-Cell Receptor Signaling Open
Kifunensine is a known inhibitor of type I α-mannosidase enzymes and has been shown to have therapeutic potential for a variety of diseases and application in the expression of high-mannose N-glycan bearing glycoproteins; however, the comp…
View article: Lectin Drug Conjugates Targeting High Mannose N‐Glycans
Lectin Drug Conjugates Targeting High Mannose N‐Glycans Open
Cancer‐associated alterations to glycosylation have been shown to aid cancer development and progression. An increased abundance of high mannose N‐glycans has been observed in several cancers. Here, we describe the preparation of lectin dr…
View article: Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation
Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation Open
View article: Functionalized High Mannose‐Specific Lectins for the Discovery of Type I Mannosidase Inhibitors
Functionalized High Mannose‐Specific Lectins for the Discovery of Type I Mannosidase Inhibitors Open
An engineered cyanovirin‐N homologue that exhibits specificity for high mannose N‐glycans has been constructed to aid type I α 1,2‐mannosidase inhibitor discovery and development. Engineering the lectins C‐terminus permitted facile functio…